Fig. 3From: Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective studyBest PSA change from baseline in PA-treated men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining who underwent pembrolizumab alone (n = 106)Back to article page